Veozah is an oral small molecule neurokinin 3 (NK3) receptor antagonist that regulates neuronal activity in the thermoregulatory center by blocking the binding of NKB to NK3 receptors on hypothalamic KNDy neurons, thereby reducing moderate to severe vasomotor symptoms associated with menopause, such as hot flashes and night sweats.

1、 Basic information of drugs

Drug name: Non zolpidem (trade name: VEOZAH) ™)

Main ingredients: The active ingredient is fezolinatant, and the excipients include iron oxide, hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, etc.

Specifications and properties: 45mg tablets.

2、 Indications, usage and dosage

Indications: Used to treat moderate to severe vasomotor symptoms caused by menopause, such as hot flashes and night sweats.

Usage and dosage: Take 45mg tablets orally once a day, both before and after meals. The whole tablet should be swallowed and not chewed. If missed, it must be taken within 12 hours, otherwise the dose will be skipped.

3、 Medication precautions

Liver function monitoring: Serum ALT, AST, and bilirubin should be tested before medication. If the transaminase level is ≥ 2 times the upper limit of normal, it is prohibited. Re examination is required at 3, 6, and 9 months after treatment and when symptoms of liver injury appear.

Omission treatment: Please replenish the missed dose as soon as possible within 12 hours after the missed dose, and skip if it is less than 12 hours.

Vomiting treatment: The instructions are not clearly stated, it is recommended to consult a doctor.

4、 Contraindications and drug interactions

Contraindications: Known cirrhosis, severe renal impairment (eGFR<30mL/min/1.73m ²), or end-stage renal disease, as well as prohibition of combination with CYP1A2 inhibitors (such as fluvoxamine, metoprolol).

Drug interaction: Combination with non zolpidem significantly increases its blood drug concentration (CYP1A2 inhibitors can increase AUC by up to 840%).

5、 Medication for special populations

For patients with liver and kidney damage: Mild to moderate liver damage (Child Pugh A/B grade) requires dose adjustment, and is contraindicated for patients with cirrhosis; Patients with moderate to severe kidney damage are prohibited from using it, while those with mild kidney damage do not need to adjust the dosage.

Pregnant women and lactation period: No human data available, animal experiments have shown that high doses pose a risk of embryonic mortality. Use with caution during lactation.

Elderly and children: There is insufficient data on the elderly population, and safety has not been established for those under 18 years old.

6、 Adverse reactions

Common reactions (incidence rate ≥ 2%): abdominal pain, diarrhea, insomnia, back pain, hot flashes, and elevated liver transaminase.

7、 Storage

Storage method: Store at room temperature (20 ° C-25 ° C) and avoid contact with children.

Veozahinformation